Danaher (DHR) Stock Analysis
NYQ · Healthcare · Diagnostics & Research
$224.32
-0.30 (-0.13%)
DHR Interactive Price Chart & Trading Signals
DHR Stock Snapshot — Valuation, Risk & Technical Signals
DHR Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$157.69B
P/E Ratio
39.99
Forward P/E
24.12
PEG Ratio
1.34
P/B Ratio
3.00
EPS
$5.61
Dividend Yield
0.71%
52W Range
$160.93 – $242.80
Beta
0.81
Volume
0.1M
ROE
7.6%
Profit Margin
15.9%
Revenue Growth
5.5%
Gross Margin
58.8%
EV/EBITDA
22.59
Analyst Target
$230.83
The trailing price-to-earnings ratio stands at 40.0x. Forward P/E of 24.1x implies earnings expansion expected. Price-to-book is 3.00x. EV/EBITDA sits at 22.59x. Market capitalization is $157.69B. Revenue is growing at 5.5% on a trailing basis. Earnings are expanding at 59.7%. Profit margins are 15.9%. Return on equity is 7.6%. Beta of 0.81 indicates market-average volatility.
Analyst Consensus
Recommendation
Strong Buy
Low Target
$195.00
Mean Target
$230.83
High Target
$310.00
Based on 23 analysts
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
DHR Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Danaher Corporation (DHR) trades above our multi-model fair value estimate of $109.99 by approximately 51.0%. Trailing P/E: 40.0x. Profitability signals include profit margin of 15.9% and return on equity of 7.6%. Recent growth metrics show revenue growth of 5.5% and earnings growth of 59.7%. Risk profile: beta of 0.81. Consensus: strong_buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 40.0x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 5.5%
Revenue is outpacing the market.
Valuation Snapshot
Danaher Corporation (DHR) trades above our multi-model fair value estimate of $109.99 by approximately 51.0%. The trailing price-to-earnings ratio stands at 40.0x. Forward P/E of 24.1x suggests earnings compression ahead. Price-to-sales is 6.3x. Price-to-book is 3.0x. EV/EBITDA sits at 22.6x. Market capitalization is $157.69B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 5.5% on a trailing basis. Earnings are expanding at 59.7%. Profit margins are 15.9%. Return on equity is 7.6%. Return on assets is 3.9%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.81 indicates market-average volatility. Net debt position is $23.51B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $230.83 implies 2.9% upside. Target range spans $195.00 to $310.00. 23 analysts cover the stock. Consensus recommendation: strong_buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
DHR Overvalued
Danaher Corporation (DHR) trades above our multi-model fair value estimate of $109.99 by approximately 51.0%.
Frequently Asked Questions
ValuationIs DHR stock overvalued right now?
ValuationWhat is DHR fair value based on current fundamentals?
RiskHow risky is DHR compared with other stocks?
GrowthIs DHR still growing?
AnalystWhat do analysts think about DHR?
DividendDoes DHR pay a dividend?
CatalystWhat could change the investment case for DHR?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.